Cargando…
Implementing biological markers as a tool to guide clinical care of patients with pancreatic cancer
A major obstacle for the effective treatment of pancreatic ductal adenocarcinoma (PDAC) is its molecular heterogeneity, reflected by the diverse clinical outcomes and responses to therapies that occur. The tumors of patients with PDAC must therefore be closely examined and classified before treatmen...
Autor principal: | Iovanna, Juan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7704461/ https://www.ncbi.nlm.nih.gov/pubmed/33248412 http://dx.doi.org/10.1016/j.tranon.2020.100965 |
Ejemplares similares
-
Targeting Fibrosis: The Bridge That Connects Pancreatitis and Pancreatic Cancer
por: Huang, Can, et al.
Publicado: (2021) -
Clinical Applications of Classical and Novel Biological Markers of Pancreatic Cancer
por: Pekarek, Leonel, et al.
Publicado: (2022) -
The promise of epigenomic therapeutics in pancreatic cancer
por: Lomberk, Gwen A, et al.
Publicado: (2016) -
Autophagy in Pancreatic Cancer
por: Grasso, Daniel, et al.
Publicado: (2012) -
Stress Proteins and Pancreatic Cancer Metastasis
por: Cano, Carla E., et al.
Publicado: (2010)